Windtree Therapeutics Files 8-K
Ticker: WINTW · Form: 8-K · Filed: Sep 25, 2024 · CIK: 946486
| Field | Detail |
|---|---|
| Company | Windtree Therapeutics Inc /De/ (WINTW) |
| Form Type | 8-K |
| Filed Date | Sep 25, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, filing, financials
Related Tickers: WINT
TL;DR
WINT filed an 8-K on 9/25, likely with financial updates. Keep an eye out.
AI Summary
On September 25, 2024, Windtree Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and significant business events. No specific new financial figures or material events were detailed in the provided excerpt.
Why It Matters
This filing signals that Windtree Therapeutics is making official disclosures to the SEC, which could contain important updates for investors regarding the company's operations or financial health.
Risk Assessment
Risk Level: low — The filing is a standard 8-K, and the provided excerpt does not contain information that inherently increases risk.
Key Numbers
- 001-39290 — Commission File Number (SEC filing identifier)
- 94-3171943 — I.R.S. Employer Identification No. (Company tax identifier)
Key Players & Entities
- Windtree Therapeutics, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
- 2600 Kelly Road, Suite 100, Warrington, Pennsylvania 18976 (address) — Principal executive office
- Discovery Laboratories Inc /DE/ (company) — Former company name
- Ansan Pharmaceuticals Inc (company) — Former company name
- Ansan Inc (company) — Former company name
FAQ
What specific "Other Events" are being reported by Windtree Therapeutics on September 25, 2024?
The provided excerpt does not detail the specific "Other Events" being reported, only that this item is included in the 8-K filing.
What is the nature of the "Financial Statements and Exhibits" mentioned in the filing?
The excerpt indicates that financial statements and exhibits are part of the filing, but does not specify their content or any new financial data.
When was Windtree Therapeutics, Inc. incorporated?
The company was incorporated in Delaware, as indicated by the filing.
What was Windtree Therapeutics previously known as?
Windtree Therapeutics was formerly known as Discovery Laboratories Inc /DE/, Ansan Pharmaceuticals Inc, and Ansan Inc.
What is the principal executive office address for Windtree Therapeutics?
The principal executive office is located at 2600 Kelly Road, Suite 100, Warrington, Pennsylvania 18976.
Filing Stats: 484 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2024-09-25 08:05:12
Key Financial Figures
- $0.001 — h registered Common Stock , par value $0.001 per share WINT The Nasdaq Capital Ma
Filing Documents
- wint20240924c_8k.htm (8-K) — 27KB
- ex_727011.htm (EX-99.1) — 18KB
- logo.jpg (GRAPHIC) — 7KB
- 0001437749-24-029936.txt ( ) — 191KB
- wint-20240925.xsd (EX-101.SCH) — 3KB
- wint-20240925_def.xml (EX-101.DEF) — 11KB
- wint-20240925_lab.xml (EX-101.LAB) — 15KB
- wint-20240925_pre.xml (EX-101.PRE) — 11KB
- wint20240924c_8k_htm.xml (XML) — 3KB
01
Item 8.01 Other Events On September 25, 2024, Windtree Therapeutics, Inc. (the "Company") issued a press release announcing positive topline results from the Company's Phase 2b SEISMiC Extension Study of istaroxime in treating early cardiogenic shock due to heart failure. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits The following exhibits are being filed herewith: Exhibit No. Document 99.1 Press Release of Windtree Therapeutics, Inc., dated September 25, 2024, announcing positive topline results from the Company's Phase 2b SEISMiC Extension Study of istaroxime 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Dated: September 25, 2024 Windtree Therapeutics, Inc. By: /s/ Craig E. Fraser Name: Craig E. Fraser Title: President and Chief Executive Officer